HAKKYUNG KOVACS: Open Payments
NPI 1720390180 · WOODLAND PARK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,405 in 139 payments from 30 companies in 2025. Trend: 2023 $1,679 · 2024 $3,217 · 2025 $3,405
Food & beverage: $3,405
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $408 |
| Lilly USA, LLC | 6 | $286 |
| Zynex Medical, Inc. | 1 | $276 |
| Otsuka America Pharmaceutical, Inc. | 3 | $261 |
| Teva Pharmaceuticals USA, Inc. | 18 | $255 |
| Lundbeck LLC | 19 | $240 |
| Amgen Inc. | 2 | $237 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $198 |
| Genentech USA, Inc. | 6 | $195 |
| Janssen Biotech, Inc. | 2 | $140 |
Products named: REXULTI, Nexwave, KISUNLA, AUSTEDO XR, RELISTOR, UBRELVY, QULIPTA, Ocrevus.
Industry payments across NJ — which companies pay providers there.
